This webinar addresses ischemia/reperfusion injury (IRI) as a major cause of early graft dysfunction and post-transplant morbidity. Neutrophils play a central role in mediating IRI through the release of oxygen-derived free radicals and neutrophil serine proteases, whose activation depends on cathepsin C. Cathepsin C inhibition prevents the activation of neutrophil serine proteases and has shown protective effects in multiple preclinical models of inflammatory and ischemic injury. Prof. Dr. Sevil Korkmaz presents evidence from models including abdominal aortic aneurysm, vasculitis, cancer, inflammatory bowel disease, preeclampsia, and lung transplantation. 

With the recent FDA and EU approval of the cathepsin C inhibitor brensocatib, and the ongoing Phase 3 development of verducatib, clinical translation of this strategy has become increasingly feasible. 

The presentation will highlight findings from our rodent heart transplantation model, demonstrating the potential of cathepsin C inhibition to mitigate IRI and improve graft outcomes. The webinar will conclude with implications for future clinical application and directions for ongoing research. 

We look forward to your participation!

Your Köhler Campus team

About the Event

The Speaker

Registration

This event is targeted at physicians, pharmacists and healthcare professionals and is free of charge.
Register to receive the link to the live webinar using the form below.